Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
17
Recruiting, industry sponsors, Kidney and urology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed218
17 trials
Showing 1 to 17, recently updated first.
AstraZenecaAstraZeneca (AZN)
NCT07024823 · 192 participants (planned) · Start Jun 9, 2025 · Primary completion Jan 29, 2027
Drug: AZD4248; Placebo and 4 more · For: Chronic Kidney Disease
Sites: Glendale, California; Chicago, Illinois; Ann Arbor, Michigan · 5 sites in all
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07235059 · 112 participants (planned) · Start Nov 20, 2025 · Primary completion Jan 21, 2028
Drug: OJR520 · For: Chronic Kidney Disease
Sites: Miami, Florida; Berlin, Germany
- A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney DiseaseRecruiting
Ingenia Therapeutics INCIndustry
NCT07231679 · 94 participants (planned) · Start Oct 30, 2025 · Primary completion Dec 2026
Drug: IGT-303; Placebo · For: Healthy Volunteers; Chronic Kidney Disease
Sites: Chula Vista, California; Lakeland, Florida; Statesville, North Carolina · 13 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07759167 · 36 participants (planned) · Start Sep 17, 2026 · Primary completion Apr 2, 2027
Drug: REGN9933; REGN7508 and 2 more · For: End-Stage Kidney Disease (ESKD)
Sites: Ghent, Belgium
- Phase 1a Study Assessing Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016Recruiting
Pulmongene Ltd.Industry
NCT07615985 · 30 participants (planned) · Start May 29, 2026 · Primary completion Nov 30, 2026
Drug: PMG1016 Dose 1; PMG1016 Dose 2 and 2 more · For: Chronic Kidney Disease
Sites: Brisbane, Australia
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.Recruiting
Nanjing Bioheng Biotech Co., Ltd.Industry
NCT07203404 · 96 participants (planned) · Start Jul 24, 2025 · Primary completion Jul 23, 2027
Drug: RD06-05 CART Cell Injection · For: SLE; LN; ANCA Associated Vasculitis and 6 more
Sites: Shanghai, China
- Renal Impairment Study for Oral EC5026Recruiting
EicOsis Human Health Inc.Industry
NCT07694544 · 18 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 31, 2026
Drug: EC5026 oral tablet · For: Chronic Kidney Disease
Sites: Sacramento, California
- Study of BHV-1400 in IgA NephropathyRecruiting
Biohaven Therapeutics Ltd.Industry
NCT07054684 · 20 participants (planned) · Start Jul 30, 2025 · Primary completion Jul 2027
Drug: BHV-1400 · For: IgA Nephropathy
Sites: Farmington, Connecticut; Miami Lakes, Florida; Orlando, Florida · 15 sites in all
Cajal Therapeutics Inc.Industry
NCT07577817 · 72 participants (planned) · Start Jun 2026 · Primary completion Oct 2026
Drug: CTX001 With and Without Iron; CTX001 With Iron and 4 more · For: Anemia; Iron Deficiencies; Chronic Kidney Disease
Sites: Melbourne, Australia
Ono Pharmaceutical Co., Ltd.Industry
NCT07619157 · 120 participants (planned) · Start Jun 2, 2026 · Primary completion Nov 30, 2027
Drug: ONO-3310; Placebo and 3 more · For: Type2 Diabetes Mellitus; Chronic Kidney Disease
Sites: Fukuoka, Japan
- A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.Pivotal-lookingRecruiting
Beijing Mabworks Biotech Co., Ltd.Industry
NCT07375758 · 130 participants (planned) · Start Feb 5, 2026 · Primary completion Jun 2028
Drug: MIL116; Matching Placebo · For: Immunoglobulin A Nephropathy
Sites: Beijing, China
AION Healthspan, Inc.Industry
NCT06721143 · 36 participants (planned) · Start Jan 23, 2025 · Primary completion Jan 2027
Drug: AION-301; Placebo · For: Chronic Kidney Disease Stage 3
Sites: Miami, Florida · 2 sites in all
Regend TherapeuticsIndustry
NCT07275788 · 15 participants (planned) · Start Jan 8, 2026 · Primary completion Dec 2027
Drug: REGEND003 · For: Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Sites: Shanghai, China
Addpharma Inc.Industry
NCT07444385 · 44 participants (planned) · Start Feb 26, 2026 · Primary completion Apr 22, 2026
Drug: AD-116, AD-1161 · For: Benign Prostatic Hyperplasia
Sites: Seoul, South Korea
Climb Bio, Inc.Industry
NCT07248865 · 48 participants (planned) · Start Dec 2, 2025 · Primary completion Jul 2026
Drug: CLYM116; Placebo · For: Healthy Volunteers
Sites: Brisbane, Australia
Intelligem Therapeutics Australia Pty Ltd.Industry
NCT06310967 · 60 participants (planned) · Start Nov 12, 2024 · Primary completion Jul 2026
Drug: IG3018 · For: Hyperuricemia; Hypouricemia, Renal
Sites: Botany, Australia; Kotara, Australia; Camberwell, Australia · 6 sites in all
Consun Pharmaceutical GroupIndustry
NCT07021157 · 48 participants (planned) · Start Mar 9, 2025 · Primary completion Aug 7, 2025
Drug: SK-08; Placebo · For: Chronic Kidney Disease(CKD)
Sites: Hangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.